An inquiry into saffron's effects on dyslipidemia

A study of the effects of saffron petals' aqueous extract on lipid profile in patients with dyslipidemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016083017756N4

Enrollment

Registered

2016-09-15

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia. Pure hyperglyceridaemia

Interventions

Intervention 1: Intervention Group: A total of 25 patients with dyslipidemia will be selected by convenience sampling method based on inclusion criteria and assigned into this group using random digit

Treatment - Drugs

Intervention Group: A total of 25 patients with dyslipidemia will be selected by convenience sampling method based on inclusion criteria and assigned into this group using random digits table. Saffron

Control Group: A total of 25 patients with dyslipidemia will be selected by convenience sampling method based on inclusion criteria and assigned into this group using random digits table. Placebo tab

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with lipid disorders (HDL=40; LDL=130; TG=200; total cholesterol=200 mg/dl); Not receiving antidyslipidemic drugs; age from 30 to 60 years; no history of stroke or heart surgery; lack of genetic dyslipidemic disease; provision of informed consent. Exclusion criteria: use of antidyslipidemic drugs during the study; incidence of myocardial infarction or heart surgery during the study; occurrence of unexpected circumstances for the participant such as an accident, death, etc.; failure to use saffron or placebo pills during the study, even for a single day

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Triglyceride. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;Total cholesterol. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;LDL. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;HDL. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.	—

Measure

Time frame

Triglyceride. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;Total cholesterol. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;LDL. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;HDL. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.

—

Secondary

Measure	Time frame
Liver enzymes. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reyhane Hoshyar

Birjand University of Medical Sciences

reyhaneh.houshyar@gmail.com+98 938 258 8299

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026